XII Medical, which is developing neuromodulation therapy for patients with sleep apnea, said it plans to use the investment to increase its staff and enhance its technology and clinical research. The funding was led by venture capital firm Omega Funds and included Cleveland Clinic, a founding investor.
“Despite advancements in obstructive sleep apnea therapies, challenges remain that prevent millions of people from receiving adequate treatment,” Omega Funds senior associate Saoussen Ben Halima, PhD, said in an Aug. 21 statement. “We believe XII Medical developed a ground-breaking platform technology to simplify treatment, expand access and improve outcomes for patients.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.